Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

The purpose of this study is to assess the anti-tumor activity of amivantamab as a
monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to
standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC)
(Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab
when added to SoC chemotherapy (Ph1b cohorts).
Colon, Rectal
Phase I/II
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics
Amivantamab, FOLFIRI (Leucovorin, 5-FU, Irinotecan), mFOLFOX6
Eng, Cathy
Vanderbilt University


18 Years
Inclusion Criteria:

Participant must have been previously diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum

For Phase 1 dose confirmation cohorts (Cohorts Ph1b-D and Ph1b-E): Participant must have evaluable disease. For Phase 2 dose expansion cohorts (Cohorts D and E): Participant must have measurable disease according to Response Criteria in Solid Tumors (RECIST) Version 1.1. If only one measurable lesion exists, it may be used for the screening biopsy as long as baseline tumor assessment scans are performed greater than or equal to (>=) 7 days after the biopsy

Participant must have Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Participant must have a tumor lesion amenable for biopsy and agree to mandatory protocol-defined screening biopsy

A female participant of childbearing potential must have a negative serum pregnancy test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study. Note: Participant must not be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study

Exclusion Criteria:

Participant with identified mutation in Kirsten rat sarcoma viral oncogene (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B (BRAF), or epidermal growth factor receptor (EGFR) ectodomain, or ERBB2/HER2 amplification by central circulating tumor deoxyribonucleic acid (ctDNA) testing at screening

Participant with symptomatic or untreated brain metastasis

History or known presence of leptomeningeal disease

Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

To learn more about any of our clinical
trials, call 615-936-8422.